Canada - English
Canada - Français
Updated ASCO Guidelines strongly recommend use of the Oncotype DX Breast Recurrence Score® Test in node-negative and the majority of node-positive early-stage breast cancer patients
For a refined risk estimateof local recurrence
Introducing the Oncotype DX GPS redesigned report for clinically low-risk prostate cancer patients.
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Help Stage II colon cancer patients understand the power of genomics
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
See if you could be eligible for testing at no cost
Determining the next treatment decision for your mCRPC patients who have failed an androgen receptor (AR)-targeted therapy can be challenging
Have questions? We're here to help.